- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04366180
Evaluering av probiotika Lactobacillus Coryniformis K8 om COVID-19-forebygging hos helsepersonell
Multisentrisk studie for å vurdere effekten av forbruk av Lactobacillus Coryniformis K8 på helsepersonell utsatt for covid-19
The aim of the present study is to evaluate the effects of Lactobacillus coryniformis K8 consumption on the incidence and severity of Covid-19 in health workers exposed to the virus. This is a preventive study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Granada
-
Granada, Granada, Spania, 18016
- Raquel Rodriguez Blanque
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Persons over 20 years of age.
- Active healthcare personnel, who attend patients with COVID-19 disease, including all professional categories, medicine, nursing and warders.
- Ability to complete surveys.
- Signature of informed consent
Exclusion Criteria:
- Person with positive test of COVID-19 confirmed by PCR test or serology
- Person with concomitant pathology HIV, transplant, active oncology or other type of active immunosuppression
- Pregnant women or women with intention to become pregnant in the next 2 months.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Probiotic
Experimental group who will receive one capsule of Lactobacillus K8 per day (3x10^9 cfu/day). |
The probiotic group will received one capsule with Lactobacillus K8 per day (3x10^9 cfu/day) during 2 months |
|
Placebo komparator: Control
Control group who will receive a daily placebo capsule consisting of maltodextrin |
The control group will received one placebo capsule per day during 2 months |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of SARS CoV-2 infection in healthcare workers
Tidsramme: 8 weeks
|
The incidence of SARS CoV-2 infection will be confirmed by PCR or antigen test |
8 weeks
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of hospital admissions caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required hospital admission because of Covid-19 |
8 weeks
|
|
Incidence of ICU admissions caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will required ICU admission because of Covid-19 |
8 weeks
|
|
Incidence of pneumonia caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop pneumonia because of Covid-19 |
8 weeks
|
|
Incidence of oxygen support requirement caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will require oxygen support because of Covid-19 |
8 weeks
|
|
Incidence of gastrointestinal symptoms caused by SARS-CoV-2 infection
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), it will be evaluated how many of them will develop gastrointestinal symptoms because of Covid-19 |
8 weeks
|
|
Days with body's temperature > 37.5 ºC
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with body's temperature > 37.5 ºC during the course of the disease |
8 weeks
|
|
Days with cough
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with cough during the course of the disease |
8 weeks
|
|
Days with fatigue
Tidsramme: 8 weeks
|
In the healthcare workers that confirm the SARS Cov-2 infection (primary variable), number of days with fatigue during the course of the disease |
8 weeks
|
|
Medical treatment
Tidsramme: 8 weeks
|
Use of drugs (dosis and duration of the treatment) for Covid-19 treatment |
8 weeks
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Luftveisinfeksjoner
- Infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Sykdommer i luftveiene
- Lungesykdommer
- Lungebetennelse, viral
- Lungebetennelse
- Coronavirus-infeksjoner
- Coronaviridae-infeksjoner
- Nidovirales infeksjoner
- Covid-19
- Kosttilskudd
- Mat
- Kosthold, mat og ernæring
- Fysiologiske fenomener
- Mat og drikke
- Probiotika
Andre studie-ID-numre
- P054
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .